Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03824704 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
A Phase 2 study, sponsored by pharmaand.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03824704: Clinical Trial Phase 2 study, sponsored by pharmaand.
NCT03824704 is a Phase 2 study that was terminated before completion, run by pharmaand. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03824704, a Phase 2 study, was terminated before completion, sponsored by pharmaand.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is an open label Phase 2, 2-stage, 2-cohort study to evaluate rucaparib in combination with nivolumab in patients with high-grade serous or endometroid ovarian cancer. Patients entering the following cohorts must have BRCA mutational status confirmed by a central lab: * Cohort A1: No BRCA mutation in tumor; high level of LOH (loss of heterozygosity) * Cohort A2: BRCA mutation in tumor
Primary Outcome
Objective response rate (ORR) is defined as the percentage of patients with a best confirmed response of complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as assessed by the investigator.
Interventions
- DRUG Nivolumab
- DRUG Rucaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-08-23 |
| Est. Completion | 2020-08-24 |
| Phase | Phase 2 |
Why NCT03824704 stopped before completion
NCT03824704 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03824704 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03824704 about?
NCT03824704 is a clinical study titled "A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)". This is an open label Phase 2, 2-stage, 2-cohort study to evaluate rucaparib in combination with nivolumab in patients with high-grade serous or endometroid ovarian cancer. Patients entering the following cohorts must have BRCA mutational status confirmed by a central lab: * Cohort A1: No BRCA mut...
What is the current status of trial NCT03824704?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2019-08-23. Estimated completion is 2020-08-24.
What interventions are being tested in trial NCT03824704?
The interventions under investigation include: Nivolumab (DRUG), Rucaparib (DRUG).
Who is sponsoring clinical trial NCT03824704?
This trial is sponsored by pharmaand, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03824704's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI